公开(公告)号：US20100168015A1

公开(公告)日：2010-07-01

申请号：US12593321

申请日：2008-03-27

申请人： Lorea Manterola Careaga ,  Inés Noelia Casares Lagar ,  Nancy Diaz-Valdés Farray ,  Javier Dotor De Las Herrerias ,  Juan José Lasarte Sagastibelza ,  Pablo Sarobe Ugarriza ,  Jesús Prieto Valtueña ,  Francisco Borràs Cuesta

发明人： Lorea Manterola Careaga ,  Inés Noelia Casares Lagar ,  Nancy Diaz-Valdés Farray ,  Javier Dotor De Las Herrerias ,  Juan José Lasarte Sagastibelza ,  Pablo Sarobe Ugarriza ,  Jesús Prieto Valtueña ,  Francisco Borràs Cuesta

IPC分类号： A61K38/16 ,  C07K7/06 ,  C07K7/08 ,  C07K14/00 ,  C07H21/04 ,  C12N5/10 ,  C12N15/79 ,  A61K38/08 ,  A61K38/10 ,  C12P21/06

CPC分类号： C07K14/5428

摘要： The invention relates to peptides having the capacity to bind to interleukin-10 (IL-10) and their use in the treatment of clinical conditions or pathological disorders associated to IL-10 expression, particularly to a high IL-10 expression, for example, infectious diseases, tumors, cancers and acute damage conditions.

摘要翻译： 本发明涉及具有结合白细胞介素-10（IL-10）的能力的肽及其在治疗与IL-10表达相关的临床病症或病理学障碍，特别是高IL-10表达的用途中的用途， 传染病，肿瘤，癌症和急性损伤病症。

公开(公告)号：US20100267623A1

公开(公告)日：2010-10-21

申请号：US12743616

申请日：2008-11-14

申请人： Inés Noelia Casares Lagar ,  Francisco Borras Cuesta ,  Pablo Sarobe Ugarriza ,  Jesús Prieto Valtueña ,  Juan José Lasarte Sagastibelza

发明人： Inés Noelia Casares Lagar ,  Francisco Borras Cuesta ,  Pablo Sarobe Ugarriza ,  Jesús Prieto Valtueña ,  Juan José Lasarte Sagastibelza

IPC分类号： A61K38/10 ,  C07K7/08 ,  C07K14/00 ,  A61P35/00 ,  A61P31/04 ,  A61P31/10 ,  A61P31/12 ,  A61P33/02 ,  C07H21/04 ,  C12N15/63 ,  C12N1/00 ,  C12P21/06

CPC分类号： C12N5/0636 ,  C07K7/08

摘要： The invention relates to peptides of general formula (I), wherein X is absent or X is present and is X14 or X14-X15, wherein X14 and X15, independently from one another, represent an amino acid; their functional variants and fragments, and their pharmaceutically acceptable salts, having the capacity to bind to scurfin and inhibit its biological activity, therefore they regulate or block the activity of regulatory T (Treg) lymphocytes. They are applicable in the treatment of infectious and neoplastic diseases. Arg-Asp-Phe-Gln-Ser-Phe-Arg-Lys-Met-Trp-Pro-Phe- Phe-X (I)

摘要翻译： 本发明涉及通式（I）的肽，其中X不存在或X存在且为X 14或X 14 -X 15，其中X 14和X 15彼此独立地表示氨基酸; 它们的功能变体和片段及其药学上可接受的盐，具有与scurfin结合并抑制其生物活性的能力，因此它们调节或阻断调节性T（Treg）淋巴细胞的活性。 它们适用于感染性和肿瘤性疾病的治疗。 Arg-Asp-Phe-Gln-Ser-Phe-Arg-Lys-Met-Trp-Pro-Phe-Phe-X（I）

公开(公告)号：US07732397B2

公开(公告)日：2010-06-08

申请号：US10798219

申请日：2004-03-11

申请人： Matilde Bustos De Abajo ,  Jesús Prieto Valtueña ,  Juan José Lasarte Sagastibelza ,  Elena Baixeras Llano

发明人： Matilde Bustos De Abajo ,  Jesús Prieto Valtueña ,  Juan José Lasarte Sagastibelza ,  Elena Baixeras Llano

IPC分类号： A61K38/18 ,  C12N5/071

CPC分类号： A61K38/19

摘要： Use of cardiotrophin in liver diseases. The invention describes the increased expression of cardiotrophin (CT-1) during the process of hepatic regeneration coinciding with maximum proliferation of hepatocytes and the role of CT-1 as a stimulator of hepatic regeneration. Furthermore, it describes the hepatoprotective role of CT-1 in various models of acute liver damage.The importance of using CT-1 in the manufacture of compositions for use in the treatment of hepatopathies is demonstrated. The invention describes such use in various forms and methods, including the recombinant protein and the use of the gene sequences that code for CT-1.

摘要翻译： 心肌营养蛋白在肝脏疾病中的应用 本发明描述了肝再生过程中心肌营养因子（CT-1）的表达增加与肝细胞的最大增殖和CT-1作为肝再生的刺激剂的作用。 此外，它描述了CT-1在各种急性肝损伤模型中的肝保护作用。 证明了使用CT-1制造用于治疗肝病的组合物的重要性。 本发明以各种形式和方法描述了这种用途，包括重组蛋白和使用编码CT-1的基因序列。

公开(公告)号：US07528226B2

公开(公告)日：2009-05-05

申请号：US11401744

申请日：2006-04-11

申请人： Ignacio José Ezquerro Saenz ,  Juan José Lasarte Sagastibelza ,  Jesús Prieto Valtueña ,  Francisco Borras Cuesta

发明人： Ignacio José Ezquerro Saenz ,  Juan José Lasarte Sagastibelza ,  Jesús Prieto Valtueña ,  Francisco Borras Cuesta

IPC分类号： C07K2/00 ,  A61K48/00

CPC分类号： C07K14/495 ,  A61K38/00 ,  A61K48/00 ,  C07K14/71 ,  C12N2799/022

摘要： Antagonistic synthetic peptides, obtained from TGFβ1 or from its receptors in the organism, that can be used in the manufacture, both on their own, as well as the gene sequences that encode them and the recombinant systems that express them, in the manufacture of compositions for use in the treatment of liver diseases and more concretely in cases of fibrosis. The said compositions can optionally include mimotopes of the said active peptides.

摘要翻译： 从生物体中获得的TGFbeta1或其受体的拮抗性合成肽本身可以用于制造，以及编码它们的基因序列和表达它们的重组系统，在制备组合物中 用于治疗肝脏疾病，更具体地用于纤维化。 所述组合物可任选地包括所述活性肽的模拟表位。

公开(公告)号：US07501392B2

公开(公告)日：2009-03-10

申请号：US11212126

申请日：2005-08-25

申请人： Jesús Prieto Valtueña ,  Ma Pilar Civeira Murillo ,  Esther Larrea Leoz

发明人： Jesús Prieto Valtueña ,  Ma Pilar Civeira Murillo ,  Esther Larrea Leoz

IPC分类号： A61K38/21 ,  C12P21/02 ,  C12N5/00 ,  C12N5/06 ,  C12N5/04 ,  C12N5/10

CPC分类号： A61K38/212 ,  Y10S514/893 ,  Y10S514/894

摘要： The invention relates to the use of interferon alpha 5 in the treatment of viral hepatopathies. The invention describes the reduced synthesis of IFNα5 in the livers of patients with hepatitis C in comparison to healthy livers. The sub-type of IFN expressed in said healthy livers corresponded only to the subtype alpha 5 in comparison with the different sub-types expressed in ill livers. The sequence SEQ ID NO:1 shows the partial sequence of cDNA corresponding to IFNα5. These significant differences between the expression patterns of some livers an others demonstrate the importance of the use of such interferon sub-type in the fabrication of compositions useful in the treatment of viral hepatopathies. The invention discloses in details such utilization in different forms and processes, including those which use the production of recombinant proteins from sequences of the type SEQ ID NO:1.

摘要翻译： 本发明涉及干扰素α5在病毒性肝病的治疗中的应用。 本发明描述了与健康肝脏相比，丙型肝炎患者肝脏中IFNα5的合成减少。 在所述健康肝脏中表达的IFN的亚型与仅在肝脏中表达的不同亚型相比仅对应于α5亚型。 序列SEQ ID NO：1显示对应于IFNα5的cDNA的部分序列。 一些肝脏的表达模式之间的这些显着差异表明了使用这种干扰素亚型在制备可用于治疗病毒性肝病的组合物中的重要性。 本发明详细公开了不同形式和方法的这种利用，包括使用从SEQ ID NO：1的序列生产重组蛋白的那些。

公开(公告)号：US07829077B2

公开(公告)日：2010-11-09

申请号：US11922221

申请日：2006-06-16

申请人： Rafael Aldabe Arregui ,  Esther Larrea Leoz ,  María Pilar Civeira Murillo ,  Jesús Prieto Valtueña

发明人： Rafael Aldabe Arregui ,  Esther Larrea Leoz ,  María Pilar Civeira Murillo ,  Jesús Prieto Valtueña

IPC分类号： A61K38/21 ,  A61K45/00 ,  A61K39/00 ,  A61K38/00 ,  C07K14/56

CPC分类号： C07K14/5412 ,  A61K38/00 ,  A61K38/19 ,  A61K38/212 ,  C07K14/5415 ,  C07K14/5431 ,  A61K2300/00

摘要： The invention relates to the use of at least one cytokine from the IL-6 family -gp130, preferably selected from among IL-11, the leukaemia inhibitory factor (LIF), oncostatin M (OSM), cardiotrophin-1, ciliary neurotrophic factor (CNTF), the cardiotrophin-like cytokine (CLC) and combinations thereof or a DNA sequence encoding same, in the preparation of a pharmaceutical composition which is intended for combined administration with at least one IFN-α or a DNA sequence encoding same, for use in the treatment of viral diseases. The invention also relates to a pharmaceutical composition comprising a pharmaceutically-acceptable quantity of at least one cytokin from the IL-6 family −gp130 or a DNA sequence encoding same and a pharmaceutically-acceptable quantity of at least one IFN-α or a DNA sequence encoding same, a pharmaceutical kit and a method for the treatment of viral diseases with the combined administration of the aforementioned cytokines and IFN-α.

摘要翻译： 本发明涉及来自IL-6家族-gp130的至少一种细胞因子，优选选自IL-11，白血病抑制因子（LIF），制瘤素M（OSM），心肌营养因子-1，睫状神经营养因子 CNTF），心肌营养素样细胞因子（CLC）及其组合，或编码该DNA序列的DNA序列，用于制备药物组合物，其用于与至少一种IFN-α或其编码的DNA序列组合施用，以供使用 在治疗病毒性疾病。 本发明还涉及包含药学上可接受量的来自IL-6家族-gp130的至少一种细胞素的药物组合物或其编码的DNA序列和药学上可接受量的至少一种IFN-α或DNA序列 编码相同的药物试剂盒，以及通过联合给药上述细胞因子和IFN-α来治疗病毒性疾病的方法。

公开(公告)号：US20110027224A1

公开(公告)日：2011-02-03

申请号：US12887843

申请日：2010-09-22

申请人： Rafael Aldabe Arregui ,  Esther Larrea Leoz ,  María Pilar Civeira Murillo ,  Jesús Prieto Valtueña

发明人： Rafael Aldabe Arregui ,  Esther Larrea Leoz ,  María Pilar Civeira Murillo ,  Jesús Prieto Valtueña

IPC分类号： A61K38/20 ,  A61P31/12

CPC分类号： C07K14/5412 ,  A61K38/00 ,  A61K38/19 ,  A61K38/212 ,  C07K14/5415 ,  C07K14/5431 ,  A61K2300/00

摘要： The invention relates to the use of at least one cytokine from the IL-6 family −gp130, preferably selected from among IL-11, the leukaemia inhibitory factor (LIF), oncostatin M (OSM), cardiotrophin-1, ciliary neurotrophic factor (CNTF), the cardiotrophin-like cytokine (CLC) and combinations thereof or a DNA sequence encoding same, in the preparation of a pharmaceutical composition which is intended for combined administration with at least one IFN-α or a DNA sequence encoding same, for use in the treatment of viral diseases. The invention also relates to a pharmaceutical composition comprising a pharmaceutically-acceptable quantity of at least one cytokin from the IL-6 family −gp130 or a DNA sequence encoding same and a pharmaceutically-acceptable quantity of at least one IFN-α or a DNA sequence encoding same, a pharmaceutical kit and a method for the treatment of viral diseases with the combined administration of the aforementioned cytokines and IFN-α.

摘要翻译： 本发明涉及来自IL-6家族-gp130的至少一种细胞因子，优选选自IL-11，白血病抑制因子（LIF），制瘤素M（OSM），心肌营养因子-1，睫状神经营养因子 CNTF），心肌营养素样细胞因子（CLC）及其组合，或编码该DNA序列的DNA序列，用于制备药物组合物，其用于与至少一种IFN-α或其编码的DNA序列组合施用，以供使用 在治疗病毒性疾病。 本发明还涉及包含药学上可接受量的来自IL-6家族-gp130的至少一种细胞素的药物组合物或其编码的DNA序列和药学上可接受量的至少一种IFN-α或DNA序列 编码相同的药物试剂盒，以及通过联合给药上述细胞因子和IFN-α来治疗病毒性疾病的方法。

公开(公告)号：US06995133B1

公开(公告)日：2006-02-07

申请号：US09674445

申请日：1999-05-13

申请人： Jesús Prieto Valtueña ,  Ma Pilar Civeira Murillo ,  Esther Larrea Leoz

发明人： Jesús Prieto Valtueña ,  Ma Pilar Civeira Murillo ,  Esther Larrea Leoz

IPC分类号： A61K38/00 ,  A61K38/21

CPC分类号： A61K38/212 ,  Y10S514/893 ,  Y10S514/894

摘要： The invention relates to the use of interferon alpha 5 in the treatment of viral hepatopathies. The invention describes the reduced synthesis of IFNα5 in the livers of patients with hepatitis C in comparison to healthy livers. The sub-type of IFN expressed in said healthy livers corresponded only to the subtype alpha 5 in comparison with the different sub-types expressed in ill livers. The sequence SEQ ID NO:1 shows the partial sequence of cDNA corresponding to IFNα5. These significant differences between the expression patterns of some livers an others demonstrate the importance of the use of such interferon sub-type in the fabrication of compositions useful in the treatment of viral hepatopathies. The invention discloses in details such utilization in different forms and processes, including those which use the production of recombinant proteins from sequences of the type SEQ ID NO:1.

摘要翻译： 本发明涉及干扰素α5在病毒性肝病的治疗中的应用。 本发明描述了与健康肝脏相比，丙型肝炎患者肝脏中IFNα5的合成减少。 在所述健康肝脏中表达的IFN的亚型与仅在肝脏中表达的不同亚型相比仅对应于α5亚型。 序列SEQ ID NO：1显示对应于IFNα5的cDNA的部分序列。 一些肝脏的表达模式之间的这些显着差异表明了使用这种干扰素亚型在制备可用于治疗病毒性肝病的组合物中的重要性。 本发明详细公开了不同形式和方法的这种利用，包括使用从SEQ ID NO：1的序列生产重组蛋白的那些。

公开(公告)号：US07850957B2

公开(公告)日：2010-12-14

申请号：US11569303

申请日：2005-05-18

申请人： Cheng Qian ,  Min Guan ,  Cristian Smerdou Picazo ,  Jesús Prieto Valtueña

发明人： Cheng Qian ,  Min Guan ,  Cristian Smerdou Picazo ,  Jesús Prieto Valtueña

IPC分类号： A01N63/00 ,  A61K39/12 ,  C12N15/00

CPC分类号： C12N15/86 ,  A61K38/208 ,  A61K48/00 ,  C12N7/00 ,  C12N2710/10343 ,  C12N2770/36143

摘要： The present invention relates to a genic expression adenoviral hybrid vector characterized in that it contains at least the following elements, oriented in the direction 5′ to 3′: i. a first chain of adenoviral origin comprising a first inverted terminal repeat (ITR) sequence and a signal sequence for packaging of the adenovirus; ii. a first non-encoding stuffer sequence; iii. a sequence corresponding to a tissue specific promoter; iv. a chain of cDNA derived from an alphavirus, the sequence of which is partly complementary to an alphaviral RNA sequence, comprising at least a sequence encoding for at least one exogenous gene of interest; v. a polyadenylation sequence; and vi. a second adenoviral inverted terminal repeat (ITR) sequence, it preferably relates to an adenoviral hybrid vector comprising as exogenous gene of interest the therapeutic gene of mammalian interleukin IL-12 and even more preferably human interleukin hIL-12; and to the use of the hybrid vector in a process for transferring genetic material to a cell, particularly a tumor cell that preferably expresses alpha-fetoprotein (AFP), and to its use for inducing an immune response against foreign antigens.

摘要翻译： 本发明涉及一种基因表达腺病毒杂合载体，其特征在于其至少包含以5'至3'方向取向的以下元件：i。 包括第一反向末端重复序列（ITR）序列和用于包装腺病毒的信号序列的第一个腺病毒源， ii。 第一个非编码填充序列; iii。 对应于组织特异性启动子的序列; iv。 源自甲病毒病毒的cDNA链，其序列与甲病毒RNA序列部分互补，包含至少一个编码至少一种感兴趣的外源基因的序列; v。多腺苷酸化序列; 和vi。 第二种腺病毒反向末端重复（ITR）序列，优选涉及包含作为感兴趣的外源基因的哺乳动物白介素IL-12的治疗基因，甚至更优选人白细胞介素hIL-12的腺病毒杂交载体; 以及将遗传物质转移到细胞，特别是优选表达甲胎蛋白（AFP）的肿瘤细胞的方法中以及其用于诱导针对外来抗原的免疫应答的用途的用途。